Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding

Previous reports have indicated that administration of the central cannabinoid receptor (CB 1) antagonist SR141716A decreases intake of highly palatable food and drink. Disruption of normal food intake has been reported only at high doses known to disrupt spontaneous behaviors. The present study was...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology, biochemistry and behavior biochemistry and behavior, 2000-10, Vol.67 (2), p.265-270
Main Authors: Freedland, Cory S, Poston, Jillian S, Porrino, Linda J
Format: Article
Language:English
Subjects:
Animals
Behavior, Animal - drug effects
Benzoxazines
Biological and medical sciences
CB 1
Dose-Response Relationship, Drug
Drinking Behavior - drug effects
Eating - drug effects
Feeding Behavior - drug effects
Fixed-ratio schedule
Food-maintained responding
FR 15
General and cellular metabolism. Vitamins
Isobologram
Male
Medical sciences
Miscellaneous
Morpholines - pharmacology
Motor Activity - drug effects
Naphthalenes - pharmacology
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Pharmacology. Drug treatments
Piperidines - pharmacology
Pyrazoles - pharmacology
Rats
Rats, Sprague-Dawley
Receptors, Cannabinoid
Receptors, Drug - agonists
Receptors, Drug - antagonists & inhibitors
Rimonabant
SR141716A
WIN 55,212-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous reports have indicated that administration of the central cannabinoid receptor (CB 1) antagonist SR141716A decreases intake of highly palatable food and drink. Disruption of normal food intake has been reported only at high doses known to disrupt spontaneous behaviors. The present study was designed to determine if rates of responding for normal food were sensitive to the effects of cannabinoid receptor blockade. Adult, male Sprague–Dawley rats were trained to lever press for normal food pellets under a fixed-ratio 15 (FR 15) schedule of reinforcement. SR141716A (0.3–3.0 mg/kg) produced dose-dependent reductions in response rate. WIN 55,212-2 (0.3 mg/kg), a high efficacy cannabinoid agonist, given as a pre-treatment to SR141716A, significantly attenuated the rate-suppressing effects of SR141716A, suggesting a principal role of CB 1 receptors in mediating these behavioral effects. These data indicate that high palatability is not necessary to observe an anorectic effect of SR141716A.
ISSN:0091-3057
1873-5177
DOI:10.1016/S0091-3057(00)00359-2